Among patients with pre-existing diabetes, use of antihyperglycemic therapy was similar between groups in the ZEUS trial (everolimus 12/13 patients [12 insulin, 3 non-insulin therapies], CsA 12/12 [12 insulin, 4 non-insulin therapies]) and the HERAKLES trial (everolimus 16/19 [16 insulin, 3 non-insulin], CsA 22/23 [20 insulin, 9 non-insulin], everolimus/reduced CsA17/18 [17 insulin, 6 non-insulin]). The gene discussed is INS; the disease is diabetes mellitus.